Clinical trial
Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic…
NCT00015977 · University of Chicago, Other · Completed
Key facts
| NCT number | NCT00015977 |
|---|---|
| Title | Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy |
| Official title | Phase II Study of Immunization With PSMA Peptide-Pulsed Autologous PBMC Plus rhIL-12 in Patients With Metastatic Prostate Cancer |
| Lead sponsor | University of Chicago, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological |
| Interventions | PSA prostate cancer vaccine, recombinant interleukin-12 |
| Enrollment | 13 |
| Start date | Nov 1, 2001 |
| Primary completion | Mar 1, 2003 |
| Completion | Jan 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 7, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: